© 2021 Sema4. All rights reserved.
Comprehensive molecular profiling
to guide personalized cancer treatment
The Sema4 Signal portfolio offers multiple somatic profiling solutions to meet service providers’ clinical, research, and trial needs. Our somatic tests generate actionable insights that help providers treat patients today while preparing to take advantage of the insights of tomorrow.
Sema4 Signal Whole Exome/Transcriptome Sequencing (WES/WTS)
Captures data from ~18,500 genes to provide the most comprehensive molecular picture of a patient’s cancer.
Read more.
Sema4 Signal PanCancer
Reports findings on ~2,200 of the most relevant cancer driver genes, based on comprehensive WES/WTS data.
Read more.
Sema4 Signal Solid Tumor (+MSI)
Targets 161 of the most clinically relevant and actionable cancer genes using as little as 10-20 ng of tumor DNA.
Read more.
Which test best meets my patient’s needs?
| Sema4 Signal WES/WTS | Sema4 Signal PanCancer | Sema4 Signal Solid Tumor Panel (+MSI) |
|
|---|---|---|---|
| Cancer type | – Solid tumors – Hematologic malignancies | – Solid tumors – Hematologic malignancies | – Solid tumors |
| Number of genes reported on | ~18,500 | ~2,200* | 161 |
| Most suitable for | – Providers seeking the broadest data available to inform care – Researchers – Clinical Trialists | – Providers looking for the most comprehensive somatic panel | – STAT turnaround time – Smaller sample sizes** |
| Molecular alterations detected | – SNVs/InDels – Certain splice variants – CNVs – Fusions | – SNVs/InDels – Certain splice variants – CNVs – Fusions | – SNVs/InDels – Certain splice variants – CNVs – Fusions |
| Immuno-oncology biomarkers analyzed | – PD-L1 – MMR – MSI – TMB | – PD-L1 – MMR – MSI – TMB | – PD-L1 – MMR – MSI |
| Germline findings reported | – Hereditary cancer genes – Non-cancer genes, as per ACMG guidelines*** | – Hereditary cancer genes | No |
| Post-test genetic counseling | For positive germline findings | For positive germline findings | No |
| Turnaround time | 14-21 days | 14-21 days | 10-14 days <10 days for STAT |
* ~2,200 genes reported on from WES/WTS data (~18,500 genes)
** Offered as reflex testing if WES/WTS or PanCancer not possible
*** ACMG Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing (ACMG SF v2.0). PMID: 27854360
WES/WTS and PanCancer Interactive Lookup Tool
Find information on specific cancer genes included in our WES/WTS and PanCancer tests
State-of-the-art profiling, enabled by cutting-edge informatics
Sema4 Signal somatic tests are powered by a number of proprietary data tools, including:
Sema4 cancer knowledgebase
Contains comprehensive, structured data and the most current state of knowledge for over 7,000 variants, including clinical trials curated based on biomarker status by PhD oncology experts.
Sema4’s variant interpretation station for oncology
Automates clinical reporting by managing the variant curation process and recommending suitable therapies. This artificial intelligence-driven genomic platform is updated regularly with the latest literature and prioritizes clinically-significant variants, enabling providers to quickly review and leverage actionable insights.
Resources
Connect with us today
